scholarly journals High-Flow Nasal Cannulae for Respiratory Support of Preterm Infants: A Review of the Evidence

Neonatology ◽  
2012 ◽  
Vol 102 (4) ◽  
pp. 300-308 ◽  
Author(s):  
Brett J. Manley ◽  
Simone K. Dold ◽  
Peter G. Davis ◽  
Charles C. Roehr
2016 ◽  
Vol 33 (11) ◽  
pp. 1058-1061 ◽  
Author(s):  
Veronica Mardegan ◽  
Elena Priante ◽  
Elisabetta Lolli ◽  
Paola Lago ◽  
Eugenio Baraldi

Heated, humidified high-flow delivered by nasal cannulae (HHHFNC) is increasingly used for noninvasive respiratory support in preterm infants and critically ill children due to its perceived effectiveness and ease of use. Evidence from randomized controlled trials suggests that HHHFNC and continuous positive airway pressure (CPAP) are equally effective as postextubation support in preterm infants. HHHFNC is also used for weaning preterm infants from CPAP. Data on HHHFNC used as the primary support for treating respiratory distress syndrome are conflicting. HHHFNC use in preterm infants is associated with reduced nasal trauma. Inability to measure the pressure generated by HHHFNC systems is a concern because overexpansion can lead to an air leak and lung injury. Great caution is warranted when HHHFNC is used in extremely low-birth-weight infants (who were rarely included in these randomized controlled trials) because a recent retrospective study found its use is associated with a higher likelihood of bronchopulmonary dysplasia or death in this population. HHHFNC has also become popular in pediatric intensive care units and pediatric wards as a method for delivering oxygen and noninvasive respiratory support. Most published studies were conducted on infants and young children with bronchiolitis. The results of a few observational studies and two randomized trials suggest that HHHFNC therapy is effective in the treatment of bronchiolitis. This review discusses the proposed mechanisms of action behind HHHFNC, the results of observational studies, and the evidence emerging from clinical trials on the use of HHHFNC in preterm infants and children critically ill with bronchiolitis.


2015 ◽  
Vol 29 (3) ◽  
pp. 11-15
Author(s):  
Abdul Razak ◽  
Siddu Charki ◽  
N Karthik Nagesh

Neonatology ◽  
2018 ◽  
Vol 114 (1) ◽  
pp. 25-25
Author(s):  
Subhash Chandra Shaw ◽  
Kannan Venkatnarayan ◽  
Rakesh Gupta

Neonatology ◽  
2018 ◽  
Vol 115 (2) ◽  
pp. 175-181 ◽  
Author(s):  
Sanja Zivanovic ◽  
Alexandra Scrivens ◽  
Raffaella Panza ◽  
Peter Reynolds ◽  
Nicola Laforgia ◽  
...  

2019 ◽  
Vol 35 (4) ◽  
pp. 298-306 ◽  
Author(s):  
Nigel Fleeman ◽  
Yenal Dundar ◽  
Prakesh S Shah ◽  
Ben NJ Shaw

AbstractBackgroundHeated humidified high-flow nasal cannula (HHHFNC) is gaining popularity as a mode of respiratory support. We updated a systematic review and meta-analyses examining the efficacy and safety of HHHFNC compared with standard treatments for preterm infants. The primary outcome was the need for reintubation for preterm infants following mechanical ventilation (post-extubation analysis) or need for intubation for preterm infants not previously intubated (analysis of primary respiratory support)MethodsWe searched PubMed, MEDLINE, Embase, and the Cochrane Library for randomized controlled trials (RCTs) of HHHFNC versus standard treatments. Meta-analysis was conducted using Review Manager 5.3.ResultsThe post-extubation analysis included ten RCTs (n = 1,201), and the analysis of primary respiratory support included ten RCTs (n = 1,676). There were no statistically significant differences for outcomes measuring efficacy, including the primary outcome. There were statistically significant differences favoring HHHFNC versus nasal cannula positive airway pressure (NCPAP) for air leak (post-extubation, risk ratio [RR] 0.29, 95 percent confidence interval [CI] 0.11 to 0.76, I2 = 0) and nasal trauma (post-extubation: 0.35, 95 percent CI 0.27 to 0.46, I2 = 5 percent; primary respiratory support: RR 0.52, 95 percent CI 0.37 to 0.74; I2 = 27 percent). Studies, particularly those of primary respiratory support, included very few preterm infants with gestational age (GA) <28 weeks.ConclusionsHHHFNC may offer an efficacious and safe alternative to NCPAP for some infants but evidence is lacking for preterm infants with GA ≤28 weeks.


2013 ◽  
Vol 369 (15) ◽  
pp. 1425-1433 ◽  
Author(s):  
Brett J. Manley ◽  
Louise S. Owen ◽  
Lex W. Doyle ◽  
Chad C. Andersen ◽  
David W. Cartwright ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document